NeuClone Starts Trial For Ustekinumab Biosimilar
NeuLara Rival To Stelara Enters Phase I Clinical Trial
After extensive pre-clinical testing, NeuClone has commenced dosing in a Phase I clinical trial for its Stelara biosimilar candidate, NeuLara.
You may also be interested in...
Formycon has become the latest firm to announce a Phase I trial for a proposed biosimilar ustekinumab rival to Janssen’s Stelara, following hot on the heels of NeuClone.
NeuClone says pre-clinical results show the biosimilar of Janssen’s Stelara (ustekinumab) that it is developing with Serum Institute of India matches the psoriasis and Crohn’s disease brand “in both primary amino-acid sequence and three-dimensional folding”. The Australian firm is currently conducting process scale-up ahead of Phase I clinical trials scheduled for next year, while it also intends to meet with “potential commercialisation partners”.
Gene Techno Science and Kishi Kasei have struck a deal to jointly develop a Japanese aflibercept biosimilar rival to Eylea.